Avalere Health’s Post

Cell and gene therapy in the Asia-Pacific region https://lnkd.in/etktvGiz Rethinking ecosystems to enable access. In this update, we bring you the key insights from our latest webinar on access for cell and gene therapies in the Asia-Pacific (APAC) region featuring a discussion between Jose Manuel Garnica, Independent Thought-Leader and Jeff Weisel, Senior Strategic Advisor at Avalere Health. This summary of the discussion includes insights for overcoming the challenges of affordability and navigating APAC healthcare systems, especially in resource-constrained markets. We also hear why public-private partnerships and policy-shaping are key in building a future with optimal access to transformative cell and gene therapies in the region. https://lnkd.in/etktvGiz #MarketAccess #HEOR #WeAreAvalereHealth

New open access policy analysis from Institute for Clinical and Economic Review (ICER) and NEWDIGS Initiative at Tufts Medical Center analyzes the challenges and potential policy options for paying for gene therapies. https://lnkd.in/ert_jyag Gene therapies offer transformative potential but bring three interconnected challenges: determining fair prices, managing clinical uncertainty, and addressing short-term budget impacts. This paper outlines policy reforms and market-based tools to help the US healthcare system overcome these challenges, ensuring more equitable and affordable access to gene therapies as they become more prevalent. #GCT #celltherapy #genetherapy #cellandgenetherapy

Cell and gene therapy market access in the Asia-Pacific region https://lnkd.in/gDcefWnY This webinar delves into the cell and gene therapy (CGT) landscape in the Asia-Pacific (APAC) region. - Understand the evolving APAC cell and gene therapy regulatory and reimbursement landscape - Gain insights into the CGT capabilities of local biotechs in APAC and where their products are today - Discover how global learnings for overcoming hurdles to optimal CGTs access can be adapted for the APAC region - Explore critical considerations for building the necessary ecosystems to successfully deploy CGTs in the APAC region Register for the webinar https://lnkd.in/gDcefWnY #MarketAccess #HEOR #WeAreAvalereHealth

There's exciting news in the world of cell and gene therapy! Learn from experts about the latest advancements and increasing approvals of gene therapies, as well as their primary barriers and challenges. Healthcare organizations can also begin preparing now to manage them with insights from the new Vizient Pharmacy Market Outlook: https://viz.inc/46GeDzi.

Are you finding the path to commercializing cell and gene therapies complex and uncertain? Join us as we explore this intricate landscape with our guest, Wajiha Ali. Highlights: - Uncover the hurdles of patient referrals and manufacturing regulations, amplifying the complexity of these therapies. - Explore essential commercialization strategies and infrastructure needs while balancing innovation with necessity. -Learn about navigating regulatory scrutiny and stakeholder management for safer, more accessible therapies. What do you believe are the keys to facilitating the journey from scientific breakthroughs to real-world applications? #cellculture #processdevelopment #bioprocessing #celltherapymanufacturing #cellandgenetherapy #leadbiotech

How is investment in the cell and gene therapy sector shaping up this year? Our data shows that through the first half of 2024, there have been over $11 billion in deals, approaching the annual total for 2023. Dive into ARM's full quarterly data on investments, clinical trials, and total developers on our website. 📊 https://lnkd.in/ebVuvmKK #cellandgenetherapy #data

Exploring new horizons: Cell and gene therapy access in the Asia Pacific region https://lnkd.in/gDcefWnY In the Asia Pacific (APAC) region, evaluating cell and gene therapies (CGT) for reimbursement is still a relatively new concept in the context of market access. As global CGT leaders seek entry into these markets, the competitive local CGT landscape adds an extra layer of complexity. To ensure timely access to CGTs in the evolving APAC payer landscape, a profound understanding of the market access dynamics for these therapies and associated technologies is essential. Join our webinar to learn into critical considerations for building the necessary ecosystems to successfully deploy CGTs in the APAC region. https://lnkd.in/gDcefWnY #MarketAccess #HEOR #WeAreAvalereHealth

📢 Unlocking Sterility Solutions for Gene Therapies! 🌟 The article focuses on sterility challenges in cell and gene therapy manufacturing. 🧬 It highlights contamination risks that can compromise product quality. 🔬 Solutions include advanced sterilization techniques and stringent quality control measures. 💡 Collaboration among researchers and manufacturers is crucial for overcoming these obstacles. ✨ Addressing these challenges is essential for advancing effective therapies. #BioprocessUpdates #CellTherapy #GeneTherapy #SterilityChallenges #ManufacturingExcellence #ContaminationControl #QualityAssurance #AdvancedSterilization #BiotechInnovation #ResearchCollaboration #TherapyDevelopment #HealthcareAdvancements #PharmaceuticalManufacturing #LifeSciences #TherapeuticSolutions #Biomanufacturing ▷ Read the full article here: 📎 https://lnkd.in/dChmTNPU

At the Economist Impact’s Cell and Gene Therapy (CGT) 2024 Summit, experts from across the industry discussed numerous topics and challenges in the introduction of CGTs: 📌 Regulatory 📌 Manufacturing and supply chain 📌 Clinical and scientific 📌 Commercial See the attached white paper capturing important themes and takeaways from the summit, including regulatory changes and new delivery models, the need to keep conversations and practices focused on patients, and how to structure clinical trials, gather real world evidence and streamline manufacturing to help improve access to treatment. #CellAndGeneTherapy #CGT #Innovation #biopharma #EconomistImpact #curiousminds Hannah Kurth

Registration is now open for SIIA's Cell + Gene Therapy Stakeholder Forum. The development of new cell and gene therapies continues is accelerating and cost management strategies are evolving just a quickly. Join experts from a wide range of stakeholders in the self-insurance marketplace to gain a better understanding of the developments impacting payers today, and those expected in the future. Program Details & Registration | https://lnkd.in/eFGkCCRx THIS is where the business of self-insurance gets done.